Generic Name and Formulations:
Clindamycin (as phosphate) 2%; vag crm.
Indications for CLINDESSE:
1 applicatorful intravaginally once.
History of enteritis or colitis.
Monitor for pseudomembranous colitis. Do not rely on contraceptive diaphragm or condom concurrently or for 5 days after treatment. Do not have vaginal intercourse or use tampons or douches during treatment. Pregnancy (Cat.B). Nursing mothers: not recommended.
May potentiate neuromuscular blockers.
Fungal vaginosis, vulvovaginal pruritus, headache.
Prefilled applicator (5g )—1
Endocrinology Advisor Articles
- Single Blood Sample Highly Predictive for Subsequent Diabetes Diagnosis
- Adjunctive Metformin for Insulin Resistance in T1D: A Clinical Perspective
- Effect of Fructose, Allulose on Postprandial Glucose Regulation in Type 2 Diabetes
- Sex Hormone Levels May Affect Postmenopausal Heart Disease Risk
- Menopausal Hormone Therapy Slows Cognitive Decline in Postmenopausal Women
- Diabetes Treatments
- Metformin May Decrease Colorectal Cancer Risk Among Males With Diabetes
- SGLT2 Inhibitor, GLP-1 Receptor Agonist Combination Treatment for Type 2 Diabetes: Expert Insights
- Semaglutide May Induce Weight Loss in Type 2 Diabetes Despite BMI
- FDA Clears Omnipod DASH System for Diabetes Management
- Effect of Infant Feeding Practices and Gut Microbiota on Overweight in First Year
- Empagliflozin, Linagliptin Combination Therapy vs Linagliptin Monotherapy for Type 2 Diabetes
- Cleared Blood Glucose Monitor Systems Not Always Accurate
- CDC: Obesity Prevalence Higher in Non-Metropolitan Counties
- Vascular Mortality Declining in Adults With Diabetes in the United States